Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 20 tulemused
Inhibition of anthrax lethal factor protease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention generally relates to inhibitors of anthrax lethal factor protease activity.
2. Description of the Related Art
Anthrax, a disease caused by Bacillus anthracis, has recently been the subject of intense interest because of its
Anthrax lethal factor is a MAPK kinase protease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to tranformed
Anthrax lethal factor is a MAPK kinase protease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable.
FIELD OF THE INVENTION
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as
Anthrax lethal factor is a MAPK kinase protease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable.
FIELD OF THE INVENTION
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as
Anthrax lethal factor is a MAPK kinase protease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable.
FIELD OF THE INVENTION
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as
Anthrax lethal factor is a mapk kinase protease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable.
FIELD OF THE INVENTION
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as
Peptide biosensors for anthrax protease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention is in the field of fluorescence-based cell and molecular biochemical assays for toxin detection and drug discovery.
BACKGROUND OF THE INVENTION
Bacillus anthracis is the causative agent of anthrax, which is characterized by the hyperstimulation of host
Engineered anthrax protective antigen proteins for cancer therapy
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
SEQUENCE LISTING
A sequence listing in electronic (ASCII text file) format is filed with this application and incorporated herein by reference. The name of the ASCII text file is "2016_ 0823A_ST25.txt"; the file was created on Aug. 18, 2016; the size of the file is 74 KB.
BACKGROUND
Proteolytic
Inhibitors of lethal factor protease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The development of new biodefense therapeutics against anthrax and botulinum neurotoxins (BoNT) has heightened with the recent threat of these agents being used as biological weapons. Lethal factor (LF), a component of the anthrax tripartite exotoxin, cleaves
Anthrax toxin fusion proteins and related methods
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The targeting of cytotoxic or other moieties to specific cell types has been proposed as a method of treating diseases such as cancer. Various toxins including Diphtheria toxin and Pseudomonas exotoxin A have been suggested as potential candidate toxins for this type of
Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to compositions and methods for inhibition of bacterial infections comprising Gram negative, Gram positive, and acid fast bacilli in general and mycobacterium tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular, as well
Bacillus anthracis protective antigen nucleic acid sequences
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines.
BACKGROUND
Anthrax, a potentially fatal disease, is caused by Bacillus anthracis. The virulence of this pathogen is mediated by a capsule of a
Methods of using Bacillus anthracis protective antigen sequences for vaccination
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines.
BACKGROUND
Anthrax, a potentially fatal disease, is caused by Bacillus anthracis. The virulence of this pathogen is mediated by a capsule of a
Methods for preparing Bacillus anthracis protective antigen for use in vaccines
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines.
BACKGROUND
Anthrax, a potentially fatal disease, is caused by Bacillus anthracis. The virulence of this pathogen is mediated by a capsule of a
Recombinant modified Bacillus anthracis protective antigen for use in vaccines
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to improved methods for preparing Bacillus anthracis mutants and for producing recombinant Bacillus anthracis protective antigen (PA) for use in vaccines.
BACKGROUND OF THE INVENTION
Anthrax, a potentially fatal disease, is caused by Bacillus anthracis.
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
